On May 6, 2015, ProMetic Life Sciences completed the bought deal public offering of common shares in the capital of the Corporation (the Offering) through a syndicate of underwriters led by Canaccord Genuity Corp., and which included RBC Dominion Securities Inc., Beacon Securities Limited, TD Securities Inc. and Paradigm Capital Inc. (collectively, the Underwriters). ProMetic issued 22,137,500 common shares of the Corporation (including the full exercise of the over-allotment option) in connection with the Offering at a price of $2.60 per share for aggregate gross proceeds of $57,557,500.
Borden Ladner Gervais LLP represented ProMetic with a team led by Pascal de Guise that included Yaniv Saragosti, Maxime Lemoyne, Lyne St Pierre, Janinna Romanini, Kenza Bensaid and Johanne Thomas. Stikeman Elliott LLP represented the underwriters with a team of Martin Langlois, Ryan Kirvan and J.B. Elliott (securities) and Jill Winton (tax). Paul, Weiss, Rifkind, Wharton & Garrison LLP represented ProMetic as US counsel with a team of Andrew Foley and Emilia Baack (corporate and securities).
